Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.796 USD | -3.75% | -10.96% | -1.17% |
04-25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
04-25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.17% | 81.83M | |
+33.37% | 700B | |
-4.89% | 358B | |
+18.86% | 330B | |
+3.37% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+5.67% | 161B | |
-2.19% | 157B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- Hookipa Pharma : Releases Positive Interim Data From Study of Potential HPV+ Cancer Drug